Roche has released its Liver Disease Panel, a comprehensive suite of certified algorithms for chronic liver disease management. This panel includes LiverPRO, an algorithm requiring only age and common blood markers for fibrosis detection. The panel aims to improve early detection and management of chronic liver disease, a global health concern affecting 1.5 billion people. By combining biomarkers and algorithms, the panel supports informed clinical decisions across the patient pathway. The Liver Disease Panel will help in the early identification of risks and in providing proactive care. LiverPRO, developed with Evido, is endorsed as a first-line test by EASL. The Liver Disease Panel is available on the navify Algorithm Suite and integrates with existing hospital systems. Roche's investment in digital diagnostics aims to advance the standard of care in liver disease. The digital solutions are designed to standardize patient referrals.